Acer Therapeutics Inc.
Newton, MA · Founded 2018 · CIK 0001069308 · Biotech · Acquired
Rare disease therapeutics, including sealtide (sialic acid supplement for lysosomal storage disorders) and other small molecule treatments
acertx.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $8.2M
- 7 Form D · Dec 2022
- 46 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 35
- 5 granted · 30 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20082010201220142016201820202022
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $1,101,000 | |
| Private capital raised | Form D · SEC | $4,085,000 | |
| Private capital raised | Form D · SEC | $15,000,000 | |
| Private capital raised | Form D · SEC | $650,000 | |
| Private capital raised | Form D · SEC | $857,493 | |
| Private capital raised | Form D · SEC | $1,499,999 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1601 | AllRock Bio | — | — |
| 1602 | TURTLETREE LABS INC. | — | — |
| 1603 | Maxwell Biosciences, Inc. | — | $11M |
| 1604 | Acer Therapeutics Inc. | — | $8.2M |
| 1605 | CeleCor Therapeutics, Inc. | — | $3.7M |
| 1606 | THERALINK TECHNOLOGIES, INC. | — | $2.6M |
| 1607 | Reglagene, LLC | — | $1.9M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Jason AmelloDirector
- Stephen AselageDirector
- Jefferson DavisExecutive Officer
- John DunnDirector
- Michelle GriffinDirector
- Tanya HaydenExecutive Officer
- David HungDirector
- David JordenDirector · Executive Officer
- Donald JosephExecutive Officer
- John KloppExecutive Officer
- Gail MaderisDirector
- David McWilliamsDirector
- Harry PalminExecutive Officer
- Bernie PaulExecutive Officer
- Adrian QuartelExecutive Officer
- Michael RichmanDirector
- Donna RillExecutive Officer
- Chris SchellingDirector · Executive Officer
- Scott SeamanDirector
- Matthew SeibtExecutive Officer
- Jaye ThompsonExecutive Officer
- Neil WarmaDirector · Executive Officer
Patents
- Palatable Compositions Including Sodium Phenylbutyrate And Uses Thereofapplication
- Solid Forms Of Emetinegranted
- Dosage Form For Improving Palatability Of Drug Substanceapplication
- Solid Forms Of Osanetantapplication
- Solid Forms Of Emetinegranted
- Nk Antagonists For Contraceptionapplication
- Methods Of Administering Taste Masked Phenylbutyrate And Compositions Thereforapplication
- Palatable Compositions Including Sodium Phenylbutyrate And Uses Thereofapplication
- Palatable Compositions Including Sodium Phenylbutyrate And Uses Thereofgranted
- Methods Of Treating Urea Cycle Disorders And Maple Syrup Urine Diseasegranted
- Palatable Compositions Including Sodium Phenylbutyrate And Uses Thereofgranted
- Palatable Compositions Including Sodium Phenylbutyrate And Uses Thereofapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.